Trusted Resource for Clinical Trials, Protocols & Progress
Delays in laboratory result reporting can severely impact the integrity of clinical trial data, delay dosing decisions, and trigger protocol deviations. Regulatory agencies such as the FDA and EMA require that lab data—especially safety-related values—be promptly and accurately reported for patient protection and trial oversight.
Click to read the full article.
Clinical trials often involve multiple laboratory sources, such as central labs, local labs, and specialty laboratories. While this decentralized approach offers flexibility and regional accessibility, it also introduces complexities in data harmonization, system compatibility, and regulatory compliance.
Click to read the full article.
In multinational clinical trials, inconsistencies in laboratory reference ranges across countries and regions can lead to protocol deviations, data interpretation issues, and regulatory scrutiny. Variations may arise due to differences in population demographics, lab equipment, assay methodology, or even local guidelines. Harmonizing these ranges is essential for generating valid and comparable clinical data.
Click to read the full article.
In clinical trials, the selection of a central or local laboratory is rarely arbitrary. It must be driven by the clinical protocol’s scientific, logistical, and regulatory requirements. A mismatch between lab capability and protocol expectations can result in protocol deviations, delayed data availability, noncompliance, and failed inspections.
Click to read the full article.
Laboratory results form the foundation of many safety and efficacy endpoints in clinical trials. Inadequate interpretation of lab values or delayed response to data queries can jeopardize subject safety, trial timelines, and data integrity. Regulatory bodies such as the FDA and EMA have consistently emphasized the need for well-defined procedures around lab data handling—particularly when multiple labs (central and local) are involved.
Click to read the full article.
Lab data discrepancies continue to be among the top findings during FDA and EMA inspections. Whether due to delayed data entry, missing values, or mismatches between EDC and lab portals, these discrepancies pose serious risks to both patient safety and data integrity.
Click to read the full article.
In today’s global clinical trial landscape, sponsors increasingly rely on vendors for managing complex laboratory functions. From central lab testing and biomarker analysis to sample logistics and data transfer, third-party vendors have become integral to operations. However, this reliance introduces significant regulatory risks if oversight mechanisms are not robust and compliant with FDA, EMA, and ICH GCP expectations.
Click to read the full article.
In modern clinical trials, electronic data capture (EDC) systems and laboratory information management systems (LIMS) operate as distinct yet interdependent platforms. Data discrepancies between these systems can lead to delayed submissions, data integrity questions, or even rejection of regulatory filings. Regulatory agencies like the FDA and EMA require sponsors to have well-documented procedures for reconciling lab and EDC data and correcting issues using a robust CAPA framework.
Click to read the full article.
In clinical research, the timely reconciliation of laboratory data with electronic data capture (EDC) systems is critical for ensuring regulatory compliance and maintaining data integrity. Traditionally, reconciliation has been a manual, periodic process. However, sponsors and CROs are now increasingly adopting real-time dashboards to streamline this process, reduce errors, and proactively manage discrepancies. These tools offer high visibility into lab–EDC mismatches and support risk-based monitoring strategies.
Click to read the full article.
Discrepancies between laboratory data and Electronic Data Capture (EDC) systems are a major concern in clinical research. These mismatches can compromise data integrity, delay trial timelines, and raise red flags during regulatory inspections. More importantly, repeated discrepancies signal systemic issues, necessitating robust trending and CAPA mechanisms.
Click to read the full article.
